Vivo Bio Tech Secures ₹10.75 Crore Pre-Clinical Testing Contract for Novel Molecule

1 min read     Updated on 20 Aug 2025, 11:58 AM
scanx
Reviewed by
Riya DeyBy ScanX News Team
whatsapptwittershare
Overview

Vivo Bio Tech Limited has secured a pre-clinical testing contract worth ₹10.75 crores with a leading Indian pharmaceutical and agro-chemical company. The two-year contract involves comprehensive pre-clinical safety and regulatory studies for a novel molecule, including toxicity, mutagenicity, ecotoxicology studies, and analytical services. The studies will be conducted under Section 9(3) requirements for submission to the Central Insecticides Board & Registration Committee (CIBRC). This contract positions Vivo Bio Tech among top Contract Research Organizations in India, demonstrating its capability to deliver integrated pre-clinical solutions meeting national and international regulatory standards.

17216931

*this image is generated using AI for illustrative purposes only.

Vivo Bio Tech Limited has announced a significant milestone in its growth trajectory, securing a pre-clinical testing contract valued at ₹10.75 crores. The contract, awarded in collaboration with a leading Indian pharmaceutical and agro-chemical company, positions Vivo Bio Tech among an elite group of Contract Research Organizations (CROs) in India.

Contract Details

The newly secured contract spans up to two years and involves comprehensive pre-clinical safety and regulatory studies for a novel molecule. The scope of work includes:

  • Toxicity studies across multiple endpoints
  • Mutagenicity evaluations to assess genetic safety
  • Ecotoxicology studies for environmental risk assessment
  • Comprehensive analytical services

All studies will be conducted under Section 9(3) requirements, with regulatory submissions to the Central Insecticides Board & Registration Committee (CIBRC)—India's apex body for approvals.

Regulatory Compliance and Industry Standing

This contract demonstrates Vivo Bio Tech's capability to deliver integrated pre-clinical solutions that meet both national and international regulatory standards. By undertaking this comprehensive mandate, the company joins a select group of CROs in India with the infrastructure and scientific expertise to handle such complex projects.

Management Commentary

Mr. Chandrasekar Patnaik, Chief Business Officer of Vivo Bio Tech Limited, commented on the achievement: "This milestone reaffirms Vivo Bio Tech's scientific and technical excellence and strengthens our positioning as a trusted research partner for the global life sciences industry. It represents a major step forward in our mission to deliver innovative, reliable, and sustainable research services."

Strategic Implications

The contract underscores Vivo Bio Tech's growing leadership across pharmaceuticals, agrochemicals, biotechnology, and environmental sciences. It aligns with the company's long-term vision of evolving from a drug discovery services provider into a strategic co-innovator with large pharma and biotech companies.

By enabling safer and more effective products to reach global markets, Vivo Bio Tech is paving the way for future collaborations in joint drug discovery and milestone-driven partnerships. This positions the company as a benchmark for next-generation CROs in the industry.

Conclusion

The securing of this significant contract not only boosts Vivo Bio Tech's financial outlook but also enhances its reputation in the pre-clinical research domain. As the company continues to expand its capabilities and secure high-value contracts, it is well-positioned to capitalize on the growing demand for comprehensive pre-clinical testing services in the pharmaceutical and agrochemical sectors.

Historical Stock Returns for Vivo Bio Tech

1 Day5 Days1 Month6 Months1 Year5 Years
+1.25%+5.69%+10.48%-1.55%+0.96%-26.52%
Vivo Bio Tech
View in Depthredirect
like17
dislike

Vivo Bio Tech Reports Strong Q1 FY2026 Performance with 29.66% Revenue Growth

1 min read     Updated on 14 Aug 2025, 12:30 PM
scanx
Reviewed by
Radhika SahaniBy ScanX News Team
whatsapptwittershare
Overview

Vivo Bio Tech Limited announced robust Q1 FY2026 results. Total income increased by 29.66% to Rs. 2,220.72 lakhs. Profit After Tax rose by 21.93% to Rs. 155.72 lakhs. Earnings Per Share improved to Rs. 1.05. Operating Profit Margin increased to 9.04%. The company published its un-audited financial results in English and Telugu newspapers on August 14, 2025.

16700428

*this image is generated using AI for illustrative purposes only.

Vivo Bio Tech Limited , a prominent player in the biotech sector, has announced robust financial results for the first quarter ended June 30, 2025, demonstrating significant growth across key metrics.

Financial Highlights

  • Total Income: Surged by 29.66% to Rs. 2,220.72 lakhs, compared to Rs. 1,712.71 lakhs in the same quarter last year.
  • Profit Before Tax: Increased by 16.22% to Rs. 200.72 lakhs from Rs. 172.71 lakhs.
  • Profit After Tax: Rose by 21.93% to Rs. 155.72 lakhs from Rs. 127.71 lakhs.
  • Earnings Per Share: Improved to Rs. 1.05 from Rs. 0.92.

Operational Performance

The company's operational efficiency showed marked improvement:

Metric Q1 FY2026 Q1 FY2025
Operating Profit Margin 9.04% 8.33%
Net Profit Margin 7.01% 7.46%
Return on Net Worth 1.92% -

Management Commentary

While specific management comments were not provided, the consistent growth across revenue and profit metrics indicates improved operational performance and potentially successful business strategies implemented by Vivo Bio Tech.

Market Disclosure

In compliance with regulatory requirements, Vivo Bio Tech Limited has published its un-audited financial results for the first quarter ended June 30, 2025, in both English and Telugu newspapers on August 14, 2025. This adherence to transparency norms underscores the company's commitment to keeping investors and stakeholders well-informed.

Outlook

The biotech sector continues to be a focus area for innovation and growth. Vivo Bio Tech's strong performance in Q1 FY2026 positions it well to capitalize on opportunities in this dynamic industry. Investors and analysts will likely keep a close watch on the company's future quarters to assess the sustainability of this growth trajectory.

As the biotech landscape evolves, Vivo Bio Tech's ability to maintain its growth momentum and operational efficiency will be crucial factors in determining its long-term success and market position.

Historical Stock Returns for Vivo Bio Tech

1 Day5 Days1 Month6 Months1 Year5 Years
+1.25%+5.69%+10.48%-1.55%+0.96%-26.52%
Vivo Bio Tech
View in Depthredirect
like20
dislike
More News on Vivo Bio Tech
Explore Other Articles
38.80
+0.48
(+1.25%)